Purchase Option

$ 4400
$ 4000
$ 6000

Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


Primary biliary cholangitis (PBC) Disease Pipeline Drugs Assessment



Primary Biliary Cholangitis is a chronic, presumable autoimmune liver diseases which further leads to progressive cholestasis and often end-stage liver diseases. This disease was formerly called as Primary Biliary Cirrhosis. PBC is the most common disease of women. Symptoms of PBC includes fatigue, pruritus, right upper quadrant discomfort, hepatomegaly, hyperpigmentation, jaundice, splenomegaly, xerophthalmia, kayser-fleischer rings etc.

Generally 25% of patients with PBC can be diagnosed by routine blood evaluation. Diagnosis of PBC includes evaluation of levels of ceruloplasmin, bile acids, serum hyaluronate, determination of presence of antimitochondrial antibodies (AMAs) in serum by ELISA and Complement Fixation Test. Imaging studies of PBC is done by Ultrasonography, CT Scan or MRI.

Ursodeoxycholic acid (UDCA) is the main treatment for people with PBC and Obeticholic acid (OCA) is a new treatment that works by improving bile flow and reducing inflammation. Medications like antibiotics can be given to treat other symptoms of PBC like pruritis. If the liver is completely damaged then Liver transplantation is recommended.



By Trial Phase, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Novartis Pharmaceuticals
  • Janssen Research & Development, LLC
  • CymaBay Therapeutics, Inc.
  • Zydus Discovery DMCC
  • GlaxoSmithKline
  • Pfizer
  • Genfit
  • Gilead Sciences

By Molecule, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Ursodeoxycholic acid
  • Obeticholic acid
  • Elafibranor
  • Seladelpar
  • Saroglitazar magnesium
  • Abataceopt
  • Rituximab
  • Others

By Route of Administration, Primary Biliary Cholangitis pipeline drugs are segmented as:

  • Oral
  • Parenteral


Space Analysis:

  • In October 2017, NGM biopharmaceuticals initiated phase II expansion trial for Non-Alcoholic Steatohepatitis. It has completed the Phase 2a proof-of-concept trial for 28 days in patients with primary biliary cholangitis, in which the results demonstrated that there is a significant reduction of ALP (Biochemical market of liver health) along with no significant worsening of pruritus with 28 days treatment of NGM282.
  • In October 2017, Gilead Sciences completed Phase 2 studies of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH) , the results determines that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis (TIMP-1)

Report Description:

Primary Biliary Cholangitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Primary Biliary Cholangitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Primary Biliary Cholangitis disease pipeline drugs development. This report studies the dynamics of the Primary Biliary Cholangitis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Primary Biliary Cholangitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases



PBI Location Map

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

[urltag url='request-table-of-content']


  • AbbVie Inc. (U.S.)
  • ObsEva (Switzerland)
  • Bayer AG (Germany)
  • Repros Therapeutics Inc. (U.S.)

Adjacent Markets